PHIA Koninklijke Philips NV

By Sabela Ojea

Koninklijke Philips N.V. said Wednesday that it has received clearance from the U.S. Food and Drug Administration to sell a range of ultrasonic solutions aimed at the control of Covid-19 related lung and cardiac complications.

The Dutch technology company said ultrasound solutions have proved their utility in imaging peripheral lung tissue affected by pneumonia, one of the potential side effects of Covid-19.

"With this regulatory clearance we can offer clear guidance to ensure safe and effective use of ultrasound... At the same time, we are investing significantly to ramp up production globally, including at our ultrasound manufacturing plants in the U.S.," said Bich Le, senior vice president and general manager of Ultrasound at Philips.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

May 13, 2020 09:27 ET (13:27 GMT)

Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Mar 2024 to Apr 2024

Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Apr 2023 to Apr 2024